Multiple biomarker panels for early detection of ovarian cancer

Future Oncology

Volumn 2, Issue 6, 2006, Pages 733-741

  Yurkovetsky, Zoya R ^a   Linkov, Faina Y ^a   Malehorn, David E ^a   Lokshin, Anna E ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biomarker panels; Cytokines; Early detection; Ovarian cancer; Tumor markers

Indexed keywords

ADIPOCYTOKINE; ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CA 125 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; GROWTH FACTOR; HORMONE; PROTEIN; PROTEINASE; TUMOR ANTIGEN;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; DISEASE COURSE; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RELIABILITY; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UNITED STATES;

CA-125 ANTIGEN; CYTOKINES; EARLY DIAGNOSIS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33845647146     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.6.733     Document Type: Review

References (70)

1. Menon U, Jacobs L Screening for ovarian cancer. Best Pract Res. Clin. Obstet. Gynaecol. 16, 469-482 (2002).
2. Menon U, Jacobs IJ: Ovarian cancer screening in the general population. Curr. Opin. Obstet. Gynecol. 13, 61-64 (2001).
3. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell Proteomics 3, 35 5-366 (2004).
4. Jacobs I, Oram D: Screening for ovarian cancer. Biomed Pharmacother. 42, 589-596 (1988).
5. Darai E, Bringuier AF, Watker-Combrouze F, Feldmann G, Madelenant P, Scoazec JY. Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumours of the ovary. Hum. Reprod. 13, 2831-2835 (1998).
6. Callet N, Delaunay J, Pichon MF: Senum sICAM-1 (soluble intercellular adhesion molecule-1) and M-CSF (macrophage colony-stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers. Eur. J. Gynaeco. Oncol. 21, 135-140 (2000).
7. Cnota W, Sodowski K, Olesiak-Andqszczak M, Pilch-Kowalczyk M: Program for early detection of ovarian cancer for women asprophylaxis provide data municipal hospital. Wiad Lek. 57(Suppl. 1), S43-S47 (2004).
8. Niloff JM: Ovarian malignancy. Curr. Opin. Obstet. Gynecol. 3, 66-72 (1991).
9. Herbst AL: The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am. J Obstet. Gynecol. 170, 1099-1105 (1994).
10. Bast RC Jr, Knauf S, Epenetos A et al.: Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 68, 1758-1763 (1991).
11. Alexander-Sefre F, Menon U, Jacobs IJ: Ovarian cancer screetung. Hosp. Med. 63, 210-213 (2002).
12. DePriest PD, DeSimone CP: Ultrasound screening for the early detection of ovarian cancer. J. Clin. Oncol. 21, 194-199 (2003).
13. Chi DS, Hoskins WJ: Ovarian cancer controversy: when and how to use available screening methods. Medscape Womens Health 1, 3 (1996).
14. Jacobs I, Bast RC Jr: The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4, 1-12 (1989).
15. van Haaften-Day C, Shen Y, Xu F et al.: OVX1, macrophage-colony stimulating factor, and CA-125-II as minor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92, 2837-2844 (2001).
16. Woolas RP, Xu FJ, Jacobs IJ et al.: Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl Cancer Inst. 85, 1748-1751 (1993).
17. Woolas RR Conaway MR, Xu F et al.: Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol. Oncol. 59, 111-116 (1995).
18. Zhang Z, Barnhill SD, Zhang H et al.: Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol. Oncol. 73, 56-61 (1999).
19. Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY: Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol. Biomarkers Prev. 9, 1107-1111 (2000).
20. Zhang Z, Bast RC Jr, Yu Y et al.: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer Cancer Res. 64, 5882-5890 (2004).
21. Menon U, Jacobs I: Screening for ovarian cancer Best Pract. Res. Clin. Obstet. Gynaecol. 16, 469-482 (2002).
22. Jacobs IJ, Pivera H, Oram DH, Bast RC Jr: Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J. Obstet. Gynaecol. 100, 1120-1124 (1993).
23. Jacobs IJ, Skates S, Davies AP et al.: Risk of diagnosis of ovarian cancer after raised senim, CA 125 concentration: a prospective cohort study. BMJ 313, 1355-1358 (1996).
24. Jacobs IJ, Skates SJ, MacDonald N et al.: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353, 1207-1210 (1999).
25. Menon U, Talaat A, Jeyarajah AR et al.: Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br. J Cancer 80, 1644-1647 (1999).
26. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl Acad. Sci. USA 99, 6567-6572 (2002).
27. Skates SJ ZZ, Bast RC: High sensitivity and specificity for detection of ovarian cancer using mixtures of multivariate normal distribution to combine information from CA 125, CA 15-3, CA 72-4 and MCSF. Proc. Am. Soc. Clin. Oncol. 21 (Abstract 816) (2002).
28. Urban N, McIntosh MW, Andersen M, Karlan BY: Ovarian cancer screening. Hematol Oncol. Clin. North Am. 17, 989-1005 (2003).
29. Bast RC Jr, Urban N, Shridhar V et al.: Early detection of ovarian cancer: promise and reality. Cancer Treat. Res. 107, 61-97 (2002).
30. Bast RC Jr: Status ofntmor markers in ovarian cancer screening. J. Clin. Oncol. 21, 200-205 (2003).
31. Fayed ST, Ahmad SM, Kassim SK Khalifa A: The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer. Dis. Markers 14, 155-160 (1998).
32. Sliutz G, Tempfer C, Kainz C et al: Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. Anticancer Res. 15, 1127-1129 (1995).
33. Skates SJ, Horick N, Yu Y et al.: Preoperative sensitivity and specificity for early-scage ovarian cancer when combating cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22, 4059-4066 (2004).
34. Zeimet AG, Guadagni F, Marth C et al.: Value of the TAG-72 (CA72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker. Geburtshilfe Frauenheilkd 55, 195-199 (1995).
35. Schutter EM, Sohn C, Kristen P et al.: Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol. Oncol. 69, 56-63 (1998).
36. Mok SC, Chao J, Skates S et al.: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl Cancer Inst. 93, 1458-1464 (2001).
37. Scambia G, Testa U, Panici PB et al.: Interleukin-6 serum levels in patients with gynecological tumors. Int. J. Cancer 57, 318-323 (1994).
38. Sehouli J, Akdogan Z, Heinze T et al.: Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res. 23, 1115-1118 (2003).
39. McGuckin MA, Ramm LE, Joy GJ, Free KE, Ward BC: Preoperative discrimination between ovarian carcinoma, non-ovarian gynecological malignancy and benign adnexal masses using serum levels of CA125 and the polymorphic epithelial mucin antigens CASA, OSA and MSA. Int. J GynecoL Cancer 2, 119-128 (1992).
40. Xu FJ, Ramakrishnan S, Daly L et al.: Increased serum levels of macrophage colony-stimulating factor in ovarian cancer Am. J. Obstet. Gynecol. 165, 1356-1362 (1991).
41. Suzuki M, Kobayashi H, Ohwada M, Terao T, Sato I: Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary. Gynecol. Oncol. 68, 35-37 (1998).
42. Suzuki M, Ohwada M, Sato I, Nagatomo M: Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Oncology 52, 128-133 (1995).
43. Castelli M, Battaglia F, Scambia G et al.: Immunosuppressive acidic protein and CA-125 levels in patients with ovarian cancer. Oncology 48, 13-17 (1991).
44. Scambia G, Foti E, Ferrandina G et al.: Prognostic role of immunosuppressive acidic protein in advanced ovarian cancer. Am. J. Obstet. Gynecol. 175, 1606-1610 (1996).
45. El-Shalakany A, Abou-Talib Y, Shalaby HS, Sallam M: Preoperative serum inhibin levels in patients with ovarian rumors. J Obstet. Gynaecol. Res. 30, 155-161 (2004).
46. Robertson DM, Pruysers E, Burger HG, Jobling T, McNeilage J, Healy D: Inhibins and ovarian cancer. Mol. Cell Endocrinol 225, 65-71( 2004).
47. Baron AT, Boardman CH, Lafky JM et al.: Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14, 306-318 (2005).
48. Opala T, Drews K, Rzymski P, Wozniak J, Sajdak S: Evaluation of soluble intracellular adhesion molecule-1 (sICAM-1) in benign and malignant ovarian masses. Eur.J Gynaecol. Oncol. 24, 255-257 (2003).
49. McIntosh MW, Drescher C, Karlan B et al.: Combining CA 125 and SMR serum. markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 95, 9-15 (2004).
50. Ye B, Cramer DW, Skates SJ et al.: Haptoglobin-α subunit as potential serum. biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9, 2904-2911 (2003).
51. Saito M, Aoki D, Susumu N et al.: Efficient screening for ovarian cancers using a combination of rumor markers CA602 and CA546. Int. J. Gynecol. Cancer 15, 37-44 (2005).
52. Yu JK, Zheng S, Tang Y, Li L: An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J. Zhijiang Univ. Sci. B. 6, 227-231 (2005).
53. Petricoin EF, Ardekani AM, Hitt BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
54. Zhu W, Wang X, Ma Y, Rao M, Glimm J, Kovach JS: Detection of cancer-specific markers amid massive mass spectral data. Proc. Natl Acad. Sci. USA 100, 14666-14671 (2003).
55. Vlahou A, Schorge JO, Gregory BW, Coleman RL: Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J Biomed Biotechnol. 2003, 308-314 (2003).
56. Kozak KR, Amneus MW, Pusey SM et al.: Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc. Natl Acad. Sci. USA 100, 12343-12348 (2003).
57. Ardekani AM, Liotta LA, Petricoin EF 3rd: Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev. Mol. Diagn. 2, 312-320 (2002).
58. Rai AJ, Zhang Z, Rosenzweig J et al: Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab. Med. 126, 1518-1526 (2002).
59. Stevens EV, Liotta LA, Kohn EC: Proteomic analysis for early detection of ovarian cancer: a realistic approach? Int. J. Gynecol. Cancer 13(Suppl. 2), 133-139 (2003).
60. Johann DJ Jr, McGuigan MD, Patel AR et al.: Clinical protcomics and biomarker discovery. Ann. NY Acad. Sci. 1022, 295-305 (2004).
61. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ: Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61, 3869-3876 (2001).
62. Mor G, Visintin I, Lai Y et at: Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. USA 102, 7677-7682 (2005).
63. Gorelik E, Landsittel DP, Marrangoni AM et al.: Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14, 981-987 (2005),
64. Yurkovetsky Z, Lisovich A, Skates S et al.: Development of a multimarker assay for early dection of ovarian cancer. NEJM (2006) (Under review).
65. Bast RC Jr: Perspectives on the future of cancer markers. Clin. Chem. 39, 2444-2451 (1993).
66. Bast RC Jr, KJug TL, St John E et al.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883-887 (1983).
67. Borras G, Molina R, Xercavins J, Ballesta. A, Iglesias J: Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol. Oncol. 57, 205-211 (1995).
68. Hogdall CK Norgaard-Pedersen B, Mogensen O: The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. AntiCancer Res. 22, 1765-1768 (2002).
69. Peters-Engl C, Medl M, Ogris E, Leodolter, S: Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Anticancer Res. 15, 2727-2730 (1995).
70. Plebani M, Navagtia F, Basso D et al.: Combined use of urinary UGP and semin CA 125 in the diagnosis of gynecological cancers. Anticancer Res. 16, 3833-3838 (1996).